Over the past two decades, PCa screening via serum prostate-specific antigen (PSA) led to substantial increases in detection of low-risk PCas (Gleason score ≤ 6), which pose little risk of either metastatic spread or death [2,3,4,5]. The gene discussed is KLK3; the disease is posterior cortical atrophy.